CHI SHENG Business Summary

Chi Sheng Pharma & Biotech Co., Ltd. (4111.TWO) operates a diversified pharmaceutical business model centered on the manufacture and distribution of generic drugs, medical equipment, and healthcare supplements. The company generates the majority of its revenue through its injection segment, which specializes in large-volume parenterals such as hemodialysis solutions, amino acid injections, and vitamin infusions. Its secondary business segments include oral solutions (antibiotics and gastrointestinal medicines), externally applied solutions (contact lens care and antiseptics), and a growing portfolio of biotech-driven health foods. Chi Sheng maintains a dominant position in Taiwan's domestic hemodialysis market while expanding its export footprint into Mainland China and Southeast Asia. Within the competitive landscape, it contends with major local players such as Standard Chemical & Pharmaceutical (1720.TW), Nang Kuang Pharmaceutical (1752.TW), and Synmosa Biopharma (4114.TW), distinguishing itself through high-volume production efficiency and a specialized focus on renal care and critical care infusions. Leadership is currently spearheaded by Chairman and General Manager Dongmao Su (Su Dong-Mao), who oversees both strategic direction and operational execution. The company, founded in 1962, remains a family-led enterprise with significant board representation and equity held by the Su family, including directors Dongyu Su, Jiajun Su, and Yujun Su. This core leadership team brings decades of institutional knowledge in the Taiwanese pharmaceutical regulatory environment and has been instrumental in the firm's transition from a traditional chemical manufacturer to a modern biotech entity. The board is further supported by independent directors such as Tau Fang Ming and Shiyuan Chen, who provide governance oversight. While the company remains largely family-controlled, its long-standing presence on the Taipei Exchange (TPEx) since 1999 has attracted a stable base of domestic institutional and retail investors focused on its consistent dividend performance and essential role in the national healthcare infrastructure.